Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study | ReachRx